Cancer BiologybioRxiv
Days Gained Response Discriminates Treatment Response in Patients with Recurrent Glioblastoma Receiving Bevacizumab-based Therapies
K. W. Singleton, A. B. Porter, L. S. Hu…·K. R. Swanson
This study evaluates Days Gained (DG) as a metric for assessing treatment response in recurrent glioblastoma patients receiving bevacizumab-based therapies, showing its prognostic significance for survival outcomes.